...
首页> 外文期刊>Neuropsychopharmacology >The Novel Dopamine D3 Receptor Antagonist NGB 2904 Inhibits Cocaine's Rewarding Effects and Cocaine-Induced Reinstatement of Drug-Seeking Behavior in Rats
【24h】

The Novel Dopamine D3 Receptor Antagonist NGB 2904 Inhibits Cocaine's Rewarding Effects and Cocaine-Induced Reinstatement of Drug-Seeking Behavior in Rats

机译:新型多巴胺D3受体拮抗剂NGB 2904抑制可卡因的奖励作用和可卡因诱导的大鼠寻药行为的恢复

获取原文
           

摘要

Accumulating evidence indicates that dopamine (DA) D3 receptor antagonists appear highly promising in attenuating cocaine reward and relapse in preclinical models of addiction. In the present study, we investigated the effects of the novel D3-selective antagonist NGB 2904 (N-(4-[4-{2,3-dichlorophenyl}-1-piperazinyl]butyl)-3-fluorenylcarboxamide) on cocaine self-administration, cocaine-enhanced brain stimulation reward (BSR), and cocaine-triggered reinstatement of drug-seeking behavior in male Long–Evans rats. We found that: (1) acute intraperitoneal (i.p.) administration of NGB 2904 (0.1–10mg/kg) failed to alter cocaine self-administration (0.5mg/kg/infusion) under fixed-ratio 2 (FR2) reinforcement, but 1 or 5mg/kg NGB 2904 significantly lowered the break-point for cocaine self-administration under progressive-ratio (PR) reinforcement; (2) cocaine (1, 2, and 10mg/kg) significantly enhanced electrical BSR (decreased brain reward thresholds), while NGB 2904 significantly inhibited the enhancement of BSR elicited by 2mg/kg, but not 10mg/kg of cocaine; (3) NGB 2904 alone neither maintained self-administration behavior nor altered brain reward thresholds; and (4) NGB 2904 significantly inhibited cocaine-triggered reinstatement of extinguished drug-seeking behavior, but not sucrose-plus-sucrose-cue-triggered reinstatement of sucrose-seeking behavior. Overall, these data show that the novel D3-selective antagonist NGB 2904 attenuates cocaine's rewarding effects as assessed by PR self-administration, BSR, and cocaine-triggered reinstatement of cocaine-seeking behavior. Owing to these properties and to its lack of rewarding effects (as assessed by BSR and by substitution during drug self-administration), NGB 2904 merits further investigation as a potential agent for treatment of cocaine addiction.
机译:越来越多的证据表明,在成瘾的临床前模型中,多巴胺(DA)D3受体拮抗剂在减弱可卡因奖励和复发方面似乎很有希望。在本研究中,我们研究了新型D3选择性拮抗剂NGB 2904(N-(4- [4- {2,3-二氯苯基} -1-哌嗪基]丁基)-3-芴基羧酰胺)对可卡因自给药,可卡因增强的脑刺激奖励(BSR)和可卡因触发的Long-Evans雄性大鼠的寻药行为恢复。我们发现:(1)在固定比例2(FR2)强化下,NGB 2904(0.1-10mg / kg)的急性腹膜内(ip)给药未能改变可卡因的自我给药(0.5mg / kg /滴注),但是1或5mg / kg NGB 2904显着降低了进行性比例(PR)强化作用下可卡因自我给药的临界点; (2)可卡因(1、2和10mg / kg)显着增强了电BSR(降低了大脑奖赏阈值),而NGB 2904显着抑制了2mg / kg引起的BSR增强,但不抑制10mg / kg的可卡因; (3)仅NGB 2904既不维持自我管理行为,也不改变大脑奖励阈值; (4)NGB 2904显着抑制了可卡因触发的已熄灭的寻药行为的恢复,但不抑制蔗糖加蔗糖提示的蔗糖寻觅行为的恢复。总体而言,这些数据表明,通过PR自给,BSR和可卡因触发的可卡因寻找行为的恢复,新型D3选择性拮抗剂NGB 2904减弱了可卡因的奖励作用。由于这些特性及其缺乏奖励作用(通过BSR评估以及在药物自我给药过程中通过替代治疗进行评估),NGB 2904作为可卡因成瘾的潜在治疗剂值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号